Univerzita Palackého v Olomouci disponuje v současné době více než 130 patenty a užitnými vzory, které jsou připraveny pro Vaše podnikání. Kompletní seznam naleznete na webu Patentscope. Do pole pro vyhledávání zadejte, prosím, "palacky or palackeho". Případně můžete pro vyhledání českých patentů využít stránek Úřadu průmyslového vlastnictví.
Máte zájem o některý z patentů, nebo Vás zajímají další informace?
Zkontaktujte nás a my se Vám rádi budeme věnovat.
|Mgr. Petr Suchomel||Ing. Filip Auinger||Dr. Ing. Petr Kubečka|
|business development manažer||business development manažer||hlavní business development manažer|
|telefon: 585 631 438||telefon: 585 631 448||telefon: 585 631 449|
|mobil: 739 329 981||mobil: 734 261 373||mobil: 734 265 043|
|e-mail: firstname.lastname@example.org||e-mail: email@example.com||e-mail: firstname.lastname@example.org|
PCT/CZ2014/000014: 2-SUBSTITUTED-6-BIARYLMETHYLAMINO-9-CYCLOPENTYL-9H-PURINE DERIVATIVES, USE THEREOF AS MEDICAMENTS, AND PHARMACEUTICAL COMPOSITIONS
This invention relates to novel 2-substituted-6-biarylmethylamino-9-cyclopentyl-9H-purine derivatives, showing activity as specific inhibitors of growth and angiogenesis of hepatocellular carcinoma. The invention further includes pharmaceutical compositions containing the 2-substituted-6-biarylmethylamino-9-cyclopentylpurines.
PCT/CZ2014/000010: ANTIBIOTIC PREPARATION AND USE THEREOF
The invention provides a preparation containing an antibiotic, with the exclusion of β-lactam antibiotics, and silver in the form selected from nano- or microparticles and silver compound, for use in the treatment of infections caused by bacteria resistant against the antibiotic. It further provides use of this preparation for the treatment of surfaces and/or material against resistant bacteria. The invention further includes an antibiotic preparation containing a mixture of an antibiotic, with the exclusion of β-lactam antibiotics, and silver nano- or microparticles, without a chemical bond between the antibiotic and silver. The present preparations are useful in particular in human or veterinary medicine, medical tools and materials, or in cosmetics to eliminate bacterial infections caused by classical antibiotic-resistant bacteria.
PCT/CZ2012/000068: METHOD OF IMMOBILIZATION OF SILVER NANOPARTICLES ON SOLID SUBSTRATES
The two-step immobilisation of silver nanoparticles on solid substrates using polyethylenimine as adhesive and reduction linker, where the primary coating of solid substrates by polyethylenimine occurs followed by production of silver nanoparticles covalently anchored on polymer surface thanks to reduction effect of its functional groups and therefore, no nanoparticles are released to environment. The method permits working under aqueous conditions, does not use any reducing agents, stabilisers or toxic solvents and can universally be applied for anti-microbial treatments of all types of solid substrates.
PCT/CZ2011/000086: USE OF 6- SUBSTITUTED 9 - HALOGENALKYL PURINES FOR REGULATION OF GROWTH AND DEVELOPMENT OF WHOLE PLANTS, PLANT CELLS AND PLANT ORGANS; NOVEL 6 - SUBSTITUTED 9 - HALOGENALKYL PURINES
The invention relates to 6-substituted 9-halogenalkyl purine derivatives of the general formula I wherein R6 is selected from the group comprising —NH-furfuryl, —NH-(4-hydroxy-3-methylbut-2-en-1-yl), —NH-(3-methylbut-2-en-1-yl), —NH-(4-hydroxy-3-methylbutyl), —NH-(4-hydroxy-1,3-dimethylbut-2-en-1-yl), —NH-(4-hydroxy-1,3-dimethylbutyl), —NH-benzyl, —NH-phenyl, wherein benzyl, furfuryl and phenyl can be unsubstituted or optionally substituted with 1 to 3 substituents selected from the group comprising hydroxy, halogen, methyl and methoxy, and R9 is selected from the group comprising C1-C3 alkyl or C1-C3 alkenyl wherein each of the groups is substituted with one or more halogen atoms, for use in the regulation of growth and development of plant cells, organs and/or whole plants. The invention also relates to preparations containing these derivatives and to novel to 6-substituted 9-halogenalkyl purines.
PCT/CZ2011/000075: USE OF ULTRA-SMALL IRON PARTICLES FOR REMOVAL, PREVENTION, AND REDUCTION OF MASS EXPANSION OF CYANOBACTERIA WATER BLOOMS
Exploitation of ultra-small iron particles for removal, prevention, and reduction of mass expansion of cyanobacteria water blooms; these iron particles exhibit a high and selective toxicity towards cyanobacteria resting in a multiplicative and simultaneous action involving conjoined destruction of cyanobacteria cells, immobilization of the released toxins and prevention of their massive release into the water column, coagulation-flocculation effect and preventive effect connected with binding of phosphorous as a key nutrition element of cyanobacteria.
PCT/CZ2012/000123: METHOD OF DETERMINATION OF CANCER CELL DRUG SENSITIVITY TOWARDS AURORA KINASE INHIBITORS
The present invention relates to a method for determining the sensitivity and/or resistance of a patient suffering from a cancer disease to Aurora kinase inhibitor therapy, which comprises determining in vitro in the cancer cells or body fluids taken from the patient the expression of at least one gene selected from a particular group and/or determining in vitro in the cancer cells or body fluids taken from the patient the level of at least one protein selected from a particular group.
PCT/CZ2008/000118: SUBSTITUTED 6-(ALKYLBENZYLAMINO) PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES
6-(alkylbenzylamino)purine derivatives of the general formula I for use as cytokinin receptor antagonists. R1 is selected from a group which includes, but is not limited to, hydroxyl, amino, nitro, thio and alkyl group. R2 denotes one to four alkyl groups. The invention also relates to preparations containing these derivatives and methods of using the derivatives.
PCT/CZ2012/000106: CARBONIC ANHYDRASE INHIBITORS AND METHOD OF THEIR PRODUCTION
The invention describes new derivatives of boron cluster compounds of general formula (I) and their pharmaceutically acceptable salts and solvates, and their specific inhibition effect on the enzyme carbonic anhydrase IX, a protein overexpressed in cancer tissues. The invention also includes methods of synthesis and the use of the novel derivatives. The inhibitiors of human carbonic anhydrase IX of this invention can be used as active compounds of pharmaceuticals for diagnostics and/or therapy of cancer diseases. (Formula (I))
PCT/CZ2012/000103: SAMPLE SLIDE PREPARATION METHOD AND DEVICE
The present invention relates to a method for preparing a microscopy slide for analysis of a biological sample comprising i) placing the slide in a humid environment; ii) cooling the slide so that frost forms on its upper surface: and iii) applying the biological sample to the frost on the slide. It further relates to a microscopy slide preparation device for the preparation of a frosted microscopy slide, the device comprising: a humidity chamber for containing the slide; a support for holding the slide within the chamber; cooling means for cooling the slide; and humidifying means for humidifying the chamber. The invention further includes a kit comprising said microscopy slide preparation device and a fixative for adding to the biological sample.
PCT/CZ2012/000092: 6, 8- DISUBSTITUTED PURINE COMPOSITIONS AND THEIR PHARMACEUTICAL AND COSMETIC USE
6,8-Disubstituted purines which can be used in drug and cosmetic compositions and/or applications are provided. These 6,8-disubstituted purines have a wide range of biological activities, including for example anti-inflammatory, anti-senescent, as well as well as other activities which are especially useful in pharmaceutical and cosmetic applications. The 6,8-disubstituted purine compounds and compositions containing such 6,8- disubstituted purines provide growth-regulatory, differentiating, antisenescent and antiaging properties with improved selectivities and efficiencies and lower toxicities than analogues known heretofore.
PCT/CZ2011/000083: METHOD FOR ACTIVATION OF AQUEOUS SILVER NANOPARTICLE DISPERSIONS FOR SURFACE ENHANCED RAMAN SPECTROSCOPY
The invention provides a method for activation of aqueous dispersions of silver nanoparticles for purposes of surface enhanced Raman spectroscopy, wherein a solution of chloride ions is added to the aqueous dispersion of silver nanoparticles in the presence of oxygen in such an amount that the final chloride ion concentration in the activated dispersion ranges from 0.1 mol.dm-3 to 1 mol.dm-3. Preferably, oxygen is added to the dispersion in the course of activation. This method leads to recrystallization of silver particles, which is faster and more reproducible for the purposes of surface enhanced Raman spectroscopy than the particle aggregation so far known in the art.
PCT/CZ2011/000086: USE OF 6 - SUBSTITUTED 9 - HALOGENALKYL PURINES FOR REGULATION OF GROWTH AND DEVELOPMENT OF WHOLE PLANTS, PLANT CELLS AND PLANT ORGANS; NOVEL 6 - SUBSTITUTED 9 -HALOGENALKYL PURINES
The invention relates to 6-substituted 9-halogenalkyl purine derivatives of the general formula I wherein R6 is selected from the group comprising -NH-furfuryl, -NH-(4-hydroxy-3-methylbut-2-en-1-yl), -NH-(3-methylbut-2-en-1-yl), -NH-(4-hydroxy-3-methylbutyl), -NH-(4-hydroxy-1,3-dimethylbut-2-en-1-yl), -NH-(4-hydroxy-1,3-dimethylbutyl), -NH-benzyl, -NH-phenyl, wherein benzyl, furfuryl and phenyl can be unsubstituted or optionally substituted with 1 to 3 substituents selected from the group comprising hydroxy, halogen, methyl and methoxy, and R9 is selected from the group comprising C1-C3 alkyl or C1-C3 alkenyl wherein each of the groups is substituted with one or more halogen atoms, for use in the regulation of growth and development of plant cells, organs and/or whole plants. The invention also relates to preparations containing these derivatives and to novel to 6-substituted 9-halogenalkyl purines.
PCT/CZ2011/000044: SUBSTITUTION DERIVATIVES OF N6-BENZYLADENOSINE-5´-MONOPHOSPHATE, METHODS OF PREPARATION THEREOF, USE THEREOF AS MEDICAMENTS, AND THERAPEUTIC PREPARATION CONTAINING THESE COMPOUNDS
The invention relates to substitution derivatives of N6-benzyladenosine-5'- monophosphate of the general formula (I), wherein (R)n represents 1 to 4 substituents (n is in the range 1 - 4), which can be the same or different, and R is selected from the group comprising C1 to C8 alkyl, C1 to C8 alkoxy, amino, halogen, hydroxy, mercapto and nitro groups, and the pharmaceutically acceptable salts thereof. This invention also relates to methods of their preparation, their use as medicaments and in other applications, and a therapeutic composition containing these derivatives.
PCT/CZ2010/000098: CYCLOBUTAN-1,1 -DICARBOXYLATO COMPLEXES OF PLATINUM WITH N6-BENZYLADENINE DERIVATIVES, METHOD OF THEIR PREPARATION AND APPLICATION OF THESE COMPLEXES AS DRUGS IN ANTITUMOUR THERAPY
Cyclobutane-1,1-dicarboxylato complexes of platinum in the oxidation state +II and their crystal-solvates including the structural motif I or having the general formula Il expressed by the structural formula [Pt(cbdc)(L)2] Il or the general formula III expressed by the structural formula [Pt(cbdc)(L)(L')] III, where the symbols L and L' stand for N6-benzyladenine derivatives of the general formula IV bound to the platinum atom of the basic motif V through any adenine nitrogen atom independently chosen from the N1, N3, N6, N7 or N9 atoms, depending on the substitution rate of the molecules IV, where the substituents R1, R2 a R3 are independently chosen from the group of: hydrogen atom, halogen, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl, functional group and N-R'R" group, where R' and R" independently symbolize hydrogen atom, alkyl, substituted alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, cycloalkyl, substituted cycloalkyl, cycloheteroalkyl, substituted cycloheteroalkyl, cycloalkenyl, substituted cycloalkenyl, cycloheteroalkenyl, substituted cycloheteroalkenyl, aryl, substituted aryl, heteroaryl, substituted heteroaryl and functional group.
PCT/CZ2010/000067: SUBSTITUTED 6-(2-HYDROXYBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND COMPOSITIONS CONTAINING THESE DERIVATIVES
The invention relates to substituted 6-(2-hydroxybenzylamino)purines of general formula I, to their activity as cyclin-dependent kinases 2, 5, 7 and 9 inhibitors and to their use as medicaments, particularly in the treatment of disorders involving cell proliferation or inflammation. The invention further includes pharmaceutical compositions containing the substituted 6-(2-hydroxybenzylamino)purines.
PCT/CZ2010/000061: SUBSTITUTED 6-(BENZYLAMINO) PURINE RIBOSIDE DERIVATIVES, USE THEREOF AND COMPOSITIONS CONTAINING THESE DERIVATIVES
The invention relates to 2-substituted-6-(substituted benzylamino)purine riboside derivatives of the general formula I. These compounds possess antiapoptotic, anti-inflammatory and differentiating activities. The invention relates also to the compositions, which contain these derivatives as active ingredients.
PCT/CZ2010/000043: METHOD OF PRODUCTION OF SYNCHRONIZED ADHERENTLY GROWING CELL LINES AND DEVICE FOR CARRYING OUT SAID METHOD
The present invention relates to a method for production of a synchronized adherently growing cell line, wherein a culture bottle with culture medium containing adherent cell line is subjected to a vibration under standard cultivation conditions in an incubator, and after finishing the vibrational treatment, the washed- out cell fraction suspension is removed and transferred to a new culture bottle or taken for analysis. The vibration causes the washout of the poorly adhering mitotic cells to the culture medium and initiates inhibition of their proliferation. The invention further relates to a device for carrying out said method, containing a movable platform (1), flexibly mounted on a stationary support structure (3), said movable platform (1) having attachment means (10) and being connected to a vibrator (5), said vibrator being connected by a cable (6) to a vibration regulator (7) embedded in a box (8), said box (8) holding an energy supply (9).
PCT/CZ2010/000004: SUBSTITUTED 6-(2-AMINOBENZYLAMINO)PURINE DERIVATIVES, THEIR USE AS MEDICAMENTS AND PREPARATIONS CONTAINING THESE COMPOUNDS
The invention relates to new substituted 6-(2-aminobenzylamino)purines, represented by the general formula I, which can be used in CDK inhibition, in particular, in the treatment of viral infections and diseases involving cell proliferation. The invention further includes pharmaceutical preparations containing substituted 6-(2-aminobenzylamino) purines.
PCT/CZ2009/000132: TRIPERPENOID 2 - DEOXY GLYCOSIDES AND USE THEREOF AS MEDICAMENTS
The invention describes novel triterpenoid 2-deoxy glycosides of general formula I, wherein at least one of the substituents X1 and R2 contains a 2-deoxy glycosidic group, method of preparation thereof, their cytotoxic activity and a pharmaceutical formulation containing these compounds.
PCT/CZ2008/000040: THE METHOD OF SYNTHESIS OF THE IRON NANOPOWDER WITH THE PROTECTIVE OXIDIC COAT FROM NATURAL AND SYNTHETIC NANOPOWDERED IRON OXIDES AND OXIHYDROXIDES
The way of preparation of the nanopowdered iron with the protective iron oxide coat by the reduction of nanopowdered crystalline or amorphous precursor of iron oxides and oxihydroxides in the reduction atmosphere, characterized by the fact that in the course of synchronous exhaust of secondarily originating gas products, nanopowdered crystalline or amorphous iron oxide or oxihydroxide with particle size smaller than 20 nm is thermally decomposed in the reduction atmosphere at temperature higher than the minimum decomposition temperature for the given oxide or oxihydroxide and hereby formed nanopowdered iron with the protective iron oxide coat, for example FeO, is cooled in the inert atmosphere, in the process of which nitrogen, argon or another inert gas is selected as the inert atmosphere.
PCT/CZ2007/000075: DERIVATIVES OF 2-PHENYL-3-HYDROXYQUINOLINE-4(1H)-ONE AND METHODS OF THEIR PREPARATION AND UTILIZATION
Derivatives of 2-phenyl-3-hydroxyquinoline-4(1H)-one of the general formula (II), where X represents a nitro group, amino group, and Y represents an atom of halogen, oxygen or sulphur substituted by C1 to C6 alkyl or phenyl group, whereby both the alkyl and phenyl group may be further substituted and the substituents may be identical or different, or by nitrogen substituted independently by hydrogen, C1 to C6 alkyl, C1 to C6 alkyl, which may be substituted among others by halogen, hydroxy, C1 to C4 alkoxy or C1 to C4 alkylamino group, or may form a saturated or unsaturated heterocyclic ring with 5 to 7 atoms, where the individual ring atoms comprise atoms of carbon, and any of the carbon atoms may be substituted by an atom of nitrogen, sulphur or oxygen, X and Y together form an imidazo group, or imidazo group substituted by C1 to C6 alkyl, which may be substituted among others by halogen, hydroxy, C1 to C4 alkoxy or C1 to C4 alkylamino group, CHO or acetylgroup, or a heterocyclic ring with 5 to 6 atoms, where the ring atoms may be further substituted. Methods of preparation of these compounds are described. In addition, their cytostatic, cytotoxic, antiproliferation and immunosuppressive activity is described including examples of their potential pharmacological and pharmaceutical utilization.
PCT/CZ2007/000088: METHOD OF PREPARATION OF SOLUBLE FORMULATION OF WATER-INSOLUBLE PENTACYCLIC AND TETRACYCLIC TERPENOIDS, A SOLUBLE FORMULATION OF PENTACYCLIC OR TETRACYCLIC TERPENOID AND A PHARMACEUTICAL COMPOSITION CONTAINING THIS SOLUBLE FORMULATION
The invention relates to a method of preparation of a soluble formulation of water-insoluble pentacyclic and tetracyclic terpenoids, wherein the water-insoluble terpenoid having a free carboxylic, hydroxy or amino functional group is derivatized on this functional group with a substituent selected from the group comprising substituents of general formula Xa bound to the hydroxy group of the terpenoid, wherein Xa is —OC—R—COOH, substituents of general formula Xa bound to the amino group of the terpenoid, wherein Xa is —OC—R—COOH, quarternary ammonium substituents of general formula Xb bound to the carboxy group of the terpenoid, wherein Xb is —(CH2)nN+R3Y—, quarternary ammonium substituents of general formula Xc bound to the carboxy group of the terpenoid, wherein Xc je —(CH2)nR+Y—, substituents of general formula Xd bound to the carboxy group of the terpenoid, wherein Xd represents —R—COOH, glycosylic substituents Xe bound by alpha or beta glycosidic bond to the hydroxy group or to the carboxy group of the terpenoid, wherein Xe is selected from the group comprising glucosyl, galactosyl, arabinosyl, rhamnosyl, lactosyl, cellobiosyl, maltosyl and the 2-deoxyanalogues thereof, and subsequently, the prepared derivative is dissolved in the solution containing water, a cyclodextrin and optionally pharmaceutically acceptable auxiliary substances, forming an inclusion derivative with the cyclodextrin. Object of the invention is further a soluble formulation of a pentacyclic or tetracyclic triterpenoid, containing an inclusion complex of the derivatized pentacyclic or tetracyclic terpenoid with a cyclodextrin, and optionally water and pharmaceutically acceptable auxiliary substances and further a pharmaceutical composition containing the soluble formulation.
PCT/CZ2009/000061: ION SOURCE FOR LOWER LIMITS OF DETECTION IN SPECTROMETRIC MEASUREMENTS
Ion source for lower limits of detection in mass spectrometry and ion mobility spectrometry that uses restriction of flow of gases and vapors at the outlet of ion source into the ambient atmosphere (10) and supplying an auxiliary medium into the working region of ion source (3) in order to achieve an increase of pressure in the working region of ion source (3) which leads to increase of signal intensity by order (s) of magnitude.
PCT/CZ2009/000007: SACCHARIDE LUPANE DERIVATIVES, THEIR USE AND PHARMACEUTICAL COMPOSITIONS CONTAINING THESE DERIVATIVES
This invention relates to saccharide lupane derivatives of general formula (I), wherein R denotes substituent independently selected from the group comprising hydrogen, hydroxy, amino, mercapto, alkyloxy, alkyl and saccharide group, R´ denotes substituent independently selected from the group comprising hydrogen, hydroxy, alkyl, carboxyl, acyl and saccharide group, wherein at least one of R and R´ contains a saccharide group. A further object relates to these compounds for use as medicaments and growth regulators. This invention further includes pharmaceutical compositions containing said derivatives.
PCT/CZ2008/000118: SUBSTITUTED 6-(ALKYLBENZYLAMINO)PURINE DERIVATIVES FOR USE AS CYTOKININ RECEPTOR ANTAGONISTS AND PREPARATIONS CONTAINING THESE DERIVATIVES
The invention relates to 6-(alkylbenzylamino)purine derivatives of the general formula I for use as cytokinin receptor antagonists, wherein R1 is selected from the group comprising hydroxyl, amino, nitro, thio and alkyl group, and R2 denotes one to four alkyl groups. The invention also relates to preparations containing these derivatives.
PCT/CZ2008/000074: SUBSTITUTED 6-ANILINOPURINE DERIVATIVES AS INHIBITORS OF CYTOKININ OXIDASE/DEHYDROGENASE AND PREPARATIONS CONTAINING THESE DERIVATIVES
The invention relates to substituted 6-anilinopurine derivatives of the general formula I, wherein R denotes one to five substituents independently selected from the group consisting of hydrogen, halogen, hydroxyl, amino, alkyloxy and alkyl group, and R2 denotes amino, halogen, nitro, thio, alkylthio or alkyl group for use as inhibitors of cytokinin oxidase/dehydrogenase. The invention also relates to the compositions containing these derivatives.
PCT/CZ2009/000006: METHOD FOR DETERMINING THE SENSITIVITY OF PATIENTS SUFFERING FROM A CANCER DISEASE TO BIOLOGICAL THERAPY
The invention relates to a method for determining the sensitivity of patients suffering from a cancer disease towards targeted biological therapy based on the inhibition of signaling pathways of the members of HER family (e.g., HER-1, HER-2, HER-3 and HER-4) by determining the expression of the biomarker S6 kinase or its post-translationally modified form or of the biomarkers of the activation of S6 kinase or their post-translationally modified forms in the tumor.